Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab/Nivolumab vs Standard Therapy in Later-line Metastatic Colorectal Cancer
CTR20222092Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab + relatlimab in metastatic colon cancer (mCRC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall Survival in randomized subjects with PD-L1 CPS >= 1 and Overall Survival in all randomized subjects. Started Aug 2022; status: terminated.
02
Drugs
nivolumab + relatlimab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20222092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222092.